SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Creon

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA approved April 2009; marketed)
Time to market
Already approved and on the U.S. market (since April 2009)
Why 3/10
No hard, dated catalyst is scheduled for CREON in the next ~12 months: it has been FDA-approved since April 30, 2009 (the only catalyst on record locally), with no pending PDUFA, pivotal readout, or label-expansion decision in SecBot's FDA data, and it is a small, mature brand inside a large diversified portfolio, so impactScore is capped at 3.
Actionable Insight NEUTRAL

Watch AbbVie's quarterly segment disclosures and the PERT competitive landscape (generic entry, pricing) for erosion signals, since those are the only ways this drug shows up in the stock's fundamentals.

Price Chart

Loading chart...

Executive Summary

CREON (pancrelipase) is AbbVie's pancreatic enzyme replacement therapy (PERT), delayed-release capsules of porcine-derived digestive enzymes (lipase, protease, amylase), used to treat exocrine pancreatic insufficiency (EPI) in cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions. It was FDA-approved in April 2009 and has been a commercial mainstay ever since; official AbbVie/HCP pages and AbbVie's own 10-K reference describe it as a pancreatic enzyme therapy for EPI. It is a mature, market-leading branded product with no pending regulatory binary, and it sits inside a large-cap pharma whose stock thesis is driven by other assets (analyst consensus is Buy-ish with mean target ~$270 vs ~$251 price). Third-party market reports estimate CREON at roughly $1.2–1.6B in 2024 U.S. revenues and flag generic/competitor erosion pressure.

How It Works

People with EPI don't make enough of the digestive enzymes the pancreas normally produces, so food isn't broken down and nutrients aren't absorbed. CREON replaces those enzymes: each capsule contains lipase, protease, and amylase extracted from pig pancreas glands, coated so the enzymes survive stomach acid and are released in the intestine (at pH ~5.5 or higher) where they help digest fat, protein, and carbohydrates. It is taken with every meal/snack, dosed in lipase units.

Trial Status

No ongoing pivotal trials for CREON/pancrelipase appear in SecBot's Phase 2/3 trial database or FDA catalyst feed, it is a fully commercialized product whose defining regulatory event (FDA approval) occurred in 2009. The only drug-specific catalyst on record locally is the 2009-04-30 fda_approval.

The Two-Sided Case

▲ Bull Case4
Category leader in a sticky, lifelong-dosing market: EPI patients (cystic fibrosis, chronic pancreatitis, pancreatectomy) typically stay on PERT for years, favoring brand loyalty and switch inertia.
One market-research source estimates CREON at roughly $1.2–1.6 billion in 2024 U.S. revenues and calls it the dominant domestic PERT brand (third-party estimate, not AbbVie-disclosed).
Market backdrop is still growing: the pancreatic enzyme replacement market is estimated at ~$1.85B in 2025, projected to ~$2.8B by 2032 (~6.1% CAGR), per a separate market report.
Developer is a diversified mega-cap with supportive Street positioning: ABBV analyst consensus is Buy-leaning (22 buy + 9 strong buy vs 8 hold, 0 sell) with a mean price target of $270.39 vs a $250.94 price (~11.6% implied upside), so no single mature brand is make-or-break.
▼ Bear Case5
No near-term binary: CREON has no pending PDUFA, pivotal readout, or label-expansion decision in the next ~12 months, so it cannot drive a dated share-price catalyst for ABBV.
Generic/competitor erosion: a market-research snippet claims a Viatris 'generic Creon' posted roughly $0.3–0.4B in 2024 and is eroding the originator via AB-equivalence (third-party claim, unverified).
Concentration risk in reverse: CREON is a small fraction of AbbVie's overall revenue, so even a significant CREON-specific event would move ABBV only marginally, not a re-rating driver.
Pricing and supply risk: as an old branded extract product, CREON faces U.S. pricing/reimbursement scrutiny and a porcine-source supply chain; label cautions include uric-acid elevations at high doses.
Layperson-investor trap: retail attention on CREON as a 'drug story' is mispriced, the stock's 36.7% 12-month return and analyst target revisions are driven by AbbVie's broader portfolio (e.g., immunology/oncology), not this enzyme product.

Upcoming Catalysts

  • None scheduled for CREON specifically in the next ~12 months; watch AbbVie quarterly earnings (next 8-K/earnings) for 'All Other'/segmented revenue trends that include CREON.
  • Track generic or biosimilar-type PERT entrants and any supply/manufacturing disruptions that could affect CREON share.
  • Any future FDA safety-labeling or shortage-list activity on pancreatic enzyme products would be the realistic near-term event to watch.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 15

Hover a chip for the title
1 creonhcp.com2 creoninfo.com3 creoninfo.com4 abbvieaccess.com5 rxabbvie.com6 rxabbvie.com7 drugs.com8 fda.report9 creonhcp.com10 guidelinecentral.com11 drugpatentwatch.com12 marketscreener.com13 marketpublishers.com14 pmarketresearch.com15 sec.gov